Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BXY-14
- Development stage
- Unknown
- Lead developer
- Lanzhou University
01
Overview
BXY-14: sourced facts only. name: "Inspired by this phenomenon, we rationally designed BXY-14, a derivative exhibiting cross-species TLR2 agonist activity." [PMID:41764631]; target: "Inspired by this phenomenon, we rationally designed BXY-14, a derivative exhibiting cross-species TLR2 agonist activity." [PMID:41764631]; developer: "State Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, P.R. China." [PMID:41764631]; stage: "Additionally, in murine models, BXY-14 markedly downregulated intratumoral PD-L1 expression and demonstrated synergistic efficacy with the anti-PD-L1 monoclonal antibody atezolizumab, resulting in significantly prolonged overall survival." [PMID:41764631]
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on BXY-14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BXY-14.